How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

445 results for

Wart Immune Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Children and natural health products: What a clinician should know

or consider the use of complementary and/or alternative therapies in the treatment of their children, without necessarily disclosing such use to their physician - . It is vital that physicians are knowledgeable about the various and most commonly used types of CAM treatments to promote an open dialogue about CAM with their patients. This statement discusses the most common forms of CAM used by Canadians, with a focus on natural health products (NHPs). It also provides a practical approach (...) and considers nature and the person as a whole to be interrelated. TCM theory emphasizes the importance of Qi, whose action manifests as all life phenomena, including the physical, mental and spiritual aspects. Disturbances in Qi manifest as disease. The main modalities used in TCM are traditional Chinese diagnosis, acupuncture/acupressure, traditional Chinese herbal remedies, traditional Chinese dietary therapy, traditional Children and natural health products: What a clinician should know Chinese exercise

2011 Canadian Paediatric Society

122. Guidance on adolescent sexual health

urethritis (NSU) / non-gonococcal urethritis (NGU) 28 11.6.3 Gonorrhoea 28 11.7 Male rectal discharge 29 11.7.1 Chlamydia and Lymphogranuloma venereum 29 11.7.2 Gonorrhoea 29 11.7.3 Male and female throat infection due to Gonorrhoea 29 11.8 Epididymoorchitis 29 11.9 Genital ulcer disease 30 3 11.9.1 Herpes simplex virus 30 11.9.2 Syphilis 30 11.10 Genital lumps 31 11.10.1 Genital warts – Human papilloma virus 31 11.10.2 Molluscum contagiosum Pox virus 31 11.11 Hepatitis viruses 31 11.11.1 Hepatitis A 31 (...) Scope and purpose of Guidance Excellent evidence-based guidelines on adolescent sexual and reproductive health (SRH) and HIV and Sexual Health already exist. (1) (2) (3). However, to date, specific guidance on the management of sexual and reproductive health for adolescents living with HIV is lacking. With highly active antiretroviral therapy (HAART), increasing numbers of children with perinatally acquired HIV infection are surviving to adolescence. In addition, more adolescents with HIV are being

2011 The Children's HIV Association

123. Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

Investigator likely to require additional systemic glucocorticosteroid therapy during the study, is exclusionary. History of any clinically important drug or vaccine allergy or anaphylaxis A cluster of differentiation 4 (CD4+) lymphocyte count < 500 cell/millimeters cubed (mm^3) at Screening Positive anti-keyhole limpet hemocyanin (KLH) antibodies at Screening Previous immunization with KLH Known allergy to shellfish, KLH vaccine, or hypersensitivity to proteins foreign to the body Levels of Immunoglobulin (...) issues with previous administration or if a washout period of 60 days or 5 half-lives (whichever is longer) has not occurred prior to the planned first day of dosing History of any autoimmune disease (e.g., rheumatoid arthritis, Lupus) History or current diagnosis of cancer, with the exception of non-melanoma skin cancer or cervical cancer in situ treated with apparent success with curative therapy (response duration > 5 years) Asthma, currently treated with or in the opinion of the Principal

2017 Clinical Trials

124. Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

agent (eg, capsaicin, resiniferatoxin) within 12 months of Day 1 Participant has had previous or current botulinum toxin therapy of any serotype for any urological condition Participant has had previous or current botulinum toxin therapy of any serotype for any non-urological condition within 12 weeks of Day 1 Participant has been immunized for any botulinum toxin serotype Participant has history or evidence of any pelvic or urological abnormalities, bladder surgery or disease, other than OAB (...) symptoms of OAB due to any known neurological reason (eg, spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc.) Participant has received pharmacologic therapy to treat symptoms of OAB, including nocturia, within 7 days of the start of the screening period procedures Participant uses clean intermittent catheterization (CIC) or indwelling catheter to manage urinary incontinence Participant has been treated with any intravesical pharmacologic

2017 Clinical Trials

125. Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults

of and/or unwillingness to abstain from the following medications during study participation: Heparin, including Lovenox® Warfarin Plavix® (clopidogrel bisulfate) Aspirin (greater than 81 mg) Non-steroidal anti-inflammatory drugs (NSAIDS) Any other drugs that are associated with increased likelihood of bleeding CYP3A inducer(s) and/or inhibitor(s) as specified in the MTN-026 Study-Specific Procedures (SSP) Manual Hormone-replacement therapy in tablet, injectable or gel form Known adverse reaction to any (...) requiring treatment per current World Health Organization (WHO) guidelines (http://www.who.int/hiv/pub/sti/pub6/en/) or symptomatic urinary tract infection (UTI). Infections requiring treatment include symptomatic Neisseria gonorrhea (GC), Chlamydia trachomatis (CT) infection, syphilis, active herpes simplex virus (HSV) lesions, anogenital sores or ulcers, or symptomatic genital warts, cervicitis, chancroid, pelvic inflammatory disease (PID), bacterial vaginosis (BV), symptomatic vaginal candidiasis

2017 Clinical Trials

126. IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

squamous intraepithelial neoplasia 3 or squamous vulvar intraepithelial neoplasia 3. The IRX-2 Regimen consists of a single dose of cyclophosphamide, followed by 21 days of indomethacin, zinc-containing multivitamins, and omeprazole. IRX-2, a human cell-derived biologic with multiple active cytokine components, may act as an immune booster to stimulate the immune system. Giving cyclophosphamide and IRX-2 may work better at treating cervical squamous intraepithelial neoplasia or squamous vulvar (...) . To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the treatment of CIN 3 or VIN 3: frequency of elimination of human papillomavirus (HPV) in cervical or vulvar tissue using a commercial HPV genotyping assay and viral load determination by quantitative polymerase chain reaction (PCR). IV. To evaluate multiple parameters to assess the activity of the IRX-2 regimen for the treatment of CIN 3 or VIN 3: analysis of the immune infiltrates in the resected surgical specimens. V

2017 Clinical Trials

127. ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients

of the investigator based upon the results of a medical history, physical examination, ECG, chemistry, hematology. In case of immunocompromised patients including but not limited to; patients receiving immunosuppressive therapy for any reason, patients with auto-immune disease, HIV patients, transplantation patients In case of genital warts patient group(s): have at least 3 genital warts (only applicable to Study Part 1) In case of vulvar HSIL: at least one lesion that can be accurately measured in at least one (...) referred to as usual type vulvar intraepithelial neoplasia (uVIN). Since digoxin / furosemide ICVT's mode of action is in part independent of the immune system and directly targeted to eradicate the causative HPV, we hypothesize this therapy to be of value in this specific group of individuals. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 28 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention

2017 Clinical Trials

128. Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

or swelling or limitation of movement that is not a result of infection, lupus-like lesions, and granulomas (Does not include auto- or allo-immune enteropathy which is criterion iii). Where possible and appropriate, diagnosis will be supported by histopathology or other diagnostic modality. vi. Failure to grow in height: 3rd percentile for age vii. Skin molluscum contagiosum OR warts (this criterion is satisfied if molluscum consists of 10 lesions or there are two or more lesions at each of two or more (...) treatment at restoring immune function to participants with X-linked severe combined immunodeficiency (XSCID) who are 2 to 40 years of age, and have significant impairment of immunity. Condition or disease Intervention/treatment Phase X-Linked Combined Immunodeficiency Diseases Biological: CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT Drug: Palifermin Drug: Busulfan Phase 1 Phase 2 Detailed Description: This study will evaluate the safety and effectiveness

2017 Clinical Trials

129. The use of vaccines in HIV-positive adults

a booster dose every 10 years if at risk of exposure, typically through travel [1C] • We recommend that individuals who may be occupationally exposed to diphtheria (e.g. laboratory workers) be tested for diphtheria antibodies 3 months after vaccination to confirm protective immunity, and be revaccinated if required [1C] • We recommend that following a credible or confirmed exposure to diphtheria, HIV-­-positive contacts receive post-­-exposure prophylaxis with antibiotic therapy and vaccination (...) protection against genital warts. In February 2015, the US Advisory Committee on Immunization Practices (ACIP) recommended 9vHPV as one of three HPV vaccines that can be used for routine vaccination of females, whereas 4vHPV or 9vHPV are recommended for males. ACIP recommends vaccination for women up to 26 years, males up to 21 years, MSM up to 26 years, and immunocompromised persons (including those with HIV infection) up to 26 years [2]. 9.4.2 Cost-­-effectiveness considerations HPV vaccination has

2015 British HIV Association

130. Sialanar (glycopyrronium) - for treating severe drooling of saliva in children and adolescents (aged 3 years and above) with conditions affecting the nervous system, such as cerebral palsy, epilepsy and neurodegenerative diseases

, 1970). As in a paediatric clinical trial (Zeller, 2012) no reports of mucosal irritation were reported these findings were considered without clinical relevance. Other toxicity studies No non-clinical literature describing the toxicity of glycopyrronium bromide in juvenile animals was presented. Possible toxic effects related to chronic oral administration of glycopyrronium on developing organs, such as Assessment report EMA/CHMP/436684/2016 Page 25/143 the CNS, neuroendocrine-, immune (...) ; the lower dose was used to initiate therapy and the dosage increased until a significant Assessment report EMA/CHMP/436684/2016 Page 55/143 decrease or cessation of drooling occurred. No information about final dose was given in the publication. The majority of the 22 subjects with data (out of 24) were reported to have shown improvement in both severity and frequency of drooling; no further details were provided. The results, analysed using Wilcoxon signed rank analysis, were highly significant

2016 European Medicines Agency - EPARs

131. Treatment and recommendations for homeless people/Unstably Housed Patients with HIV/AIDS

21 Education, self-management 22 Case Study: Antiretroviral Therapy for a Unstably Housed Man 28 Medications 28 Associated problems, complications 34 Case Study: Unstably Housed Transgender Adult Living with HIV 42 Follow-up 43 References 45 About the HCH Clinicians’ Network 51 HIV/AIDS Care for Unstably Housed Patients: Summary of Recommended Practice Adaptations vii Health Care for the Homeless Clinicians’ Network MODEL OF CARE Service Delivery Design ? Flexible service system – Allow walk (...) intervention, related to either HIV disease progression, new opportunistic infections (OIs) or co-morbid conditions, or potential side effects of therapy; assess for chronic symptomatology (weight loss, increasing fatigue, fevers/night sweats, cognitive dysfunction, etc.). ? Current living situation – Ask where the patient sleeps and spends time during day; document patient contact information and specify how to contact clinical team. Ask about access to food, shelter, restrooms, place to store medications

2013 National Health Care for the Homeless Council

132. Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion

with a polymerase chain reaction technique to prevent infection of the inseminated woman. VIRUS-SPECIFICRISKREDUCTIONSTRATEGIES HIV HIV-1 and HIV-2 are retroviruses that primarily infect T lymphocytes and other immune cells. HIV-1 and HIV-2 have the same modes of transmission and are associated with similar opportunistic infections and acquired immuno- de?ciency syndrome (AIDS). Infection with HIV-1 leads to AIDS and death in most untreated individuals. Immunode?- ciency associated with HIV-2 infection may (...) , the conversion of the seronegative partner was 0 in the antiretroviral-treated group compared to 61 in the non-treated group with a conversion rate of 0.02. Although many centers have demonstrated low risk of HIV seroconversion, the risk is still possible, but appears to be much better when antire- troviral therapy for the infected partner is utilized and the seropositive partner has a higher CD4 cell count >350 cells/mL. The uninfected partner in a discordant couple should be tested for HIV serology

2013 Society for Assisted Reproductive Technology

133. Anal cancer screening ? A case for screening anal paps

pose a significant barrier that dissuades clinical discussion of the test. In addition, insurance coverage for anal pap smears is very limited. Another issue that arises from anal cancer screening is the question of treatment. Unlike cervical dysplasia and localized cervical cancer, where large excisions or complete [8], anal dysplasia and cancer does not have comparable treatment capability or success. Current treatment modalities for anal dysplasia include topical agents, immune modulation (...) , cryotherapy, laser therapy and surgery. These treatments often don’t lead to a cure and are associated with recurrence rates as high as 50-85% [9]. Anal cancer is currently treated with chemoradiation and surgery, depending on oncologic staging, with an overall 5-year mortality rate of 35.1% [1]. Additionally, the cost-effectiveness of anal cancer screening is questionable. In the United States, a cost-effective screening program is determined to be one that has a treatment cost of under $30,000-50,000

2013 Clinical Correlations

134. Anal Squamous Neoplasms

. T opical 5% imiquimod cream with close long-term follow-up is an appropriate therapy for LGAIN/ HGAIN of the anal margin. Grade of Recommenda- tion: Strong recommendation based on low-quality evidence, 1C. imiquimod is an immune response modifier with both anti-HPV and antitumor effects. u se of topical 5% imi- quimod cream has support from cohort and case series. Pooled analysis has demonstrated a complete response in 48% of patients, with additional partial response in 34% at a mean follow-up (...) may be minimized with protracted application. 172,174 initial clinical response rates have been reported in up to 90%, although recurrence may occur in up to 50%. 174 Risk factors for recurrence in- clude poorly defined areas of involvement, follicular in - volvement, poor immune response, dense scar tissue, and recurrent or persistent HPV infection and poor compli- ance with therapy. 175 Local side effects are very common, occurring in up to 85%, and include skin irritation and DiSEASES

2012 American Society of Colon and Rectal Surgeons

135. What is the efficacy of duct tape as a treatment for verruca vulgaris?

varies with age, with the lowest estimates at 4% and the highest at 24% (Gibbs). Those at highest risk are young people sharing communal ‘bare-foot’ areas (Gibbs). Current first line therapies for verrucas are ‘wart paints’ usually containing salicylic acid, or cryotherapy (Gibbs). Duct tape has been proposed as alternative first line treatment. Treatment of verrucas with duct tape is known as occlusive therapy. This typically involves application of tape for seven continuous days followed by a 12 h (...) overnight rest; this cycle is repeated for a total of 6–8 weeks (Focht, de Haen, Wenner). This at first seems a bizarre idea and occlusive duct tape therapy has been controversial and has provoked much debate and prompted the conduct of three RCTs during the last 10 years, the results of which are outlined in the table. The biological plausibility for this treatment is debatable. It is thought that the duct tape acts through stimulation of the patient's immune system by causing local irritation

2011 BestBETS

136. Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder

within 12 months prior to initiation of Treatment phase 1 (Week 0). Subject has previous or current use of botulinum toxin therapy of any serotype for the treatment of any urological condition. Subject has previous use within 12 weeks prior to initiation of Treatment phase 1 (Week 0) or current use of botulinum toxin therapy of any serotype for any non-urological condition or beauty care. Subject has been immunized for botulinum toxin of any serotype. Subject cannot withhold any antiplatelet (...) -treatment will receive a second and third treatment. Each re-treatment will be with open-label GSK1358820 100 U injection, and will be spaced at least 12 weeks from the previous treatment. The total duration of participation for any subject will not exceed 52 weeks, including screening and the 48-week treatment period. Condition or disease Intervention/treatment Phase Urinary Bladder, Overactive Drug: GSK1358820 Drug: Placebo Drug: Antibiotic therapy Other: Bladder diary Other: King's Health

2016 Clinical Trials

137. Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity

or current use of botulinum toxin therapy of any serotype for the treatment of any urological condition Subject has previous use within 12 weeks prior to initiation of Treatment phase 1 (Week 0) or current use of botulinum toxin therapy of any serotype for any non-urological condition or beauty care Subject has been immunized for botulinum toxin of any serotype Subject cannot withhold any antiplatelet or anticoagulant therapy or medications with anticoagulative effects for 3 days prior to initiation (...) as: Pre-menopausal females with one of the following: Documented tubal ligation, Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Documented Bilateral Oophorectomy. Postmenopausal defined as 12 months of spontaneous amenorrhea. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during

2016 Clinical Trials

138. Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

PSRT on a case-by-case basis. Live attenuated vaccines other than influenza vaccine received within 10 days before first infusion or scheduled within 10 days after first infusion (e.g., measles, mumps, and rubella [MMR]; oral polio vaccine [OPV]; varicella; yellow fever) Previous receipt of humanized or human mAbs whether licensed or investigational Immune System Immunosuppressive medications received within 30 days before first infusion. (Not exclusionary: [1] corticosteroid nasal spray; [2 (...) or incompletely treated syphilis infection Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to: A process that would affect the immune response, A process that would require medication that affects the immune response, Any contraindication to repeated infusions or blood draws

2016 Clinical Trials

139. Study to Evaluate the Safety and Immunogenicity of Orally-administered HIV Vaccine in Healthy, HIV-uninfected Adult Participants

) Allergy treatment with antigen injections within 30 days before first vaccination or that are scheduled within 30 days after first vaccination. Immune System Immunosuppressive medications received within 168 days before first vaccination. (Not excluded: topical corticosteroids for mild, uncomplicated dermatitis; or [4] a single course of oral/parenteral corticosteroids at doses < 2 mg/kg/day and length of therapy < 11 days with completion at least 30 days prior to enrollment. Serious adverse reactions (...) Status : Active, not recruiting First Posted : May 13, 2016 Last Update Posted : July 4, 2018 Sponsor: PaxVax, Inc. Collaborator: National Institute of Allergy and Infectious Diseases (NIAID) Information provided by (Responsible Party): PaxVax, Inc. Study Details Study Description Go to Brief Summary: The purpose of this study is to test experimental human immunodeficiency virus (HIV) vaccines that use an adenovirus vector. The adenovirus vector may help the vaccines stimulate an immune response

2016 Clinical Trials

140. Immunologic Profile of Chronically Photodamaged Skin

stripping are common procedures in clinical settings to stimulate skin desired skin responses. Imiquimod 5% cream (ALDARA®) is an FDA-approved drug for the treatment of basal cell carcinomas, actinic keratoses and genital warts. Investigators will compare the reaction of the skin's immune system on a cellular level from skin normally exposed to the sun exposure to an area normally hidden from sun exposure. Condition or disease Intervention/treatment Phase Photoaged Skin Normal Skin Biological: Candida (...) is frequently used as a positive control in clinical tests to assess type I Immunoglobulin E (IgE)-mediated hypersensitivity reactions. Imiquimod 5% cream is a direct stimulator of toll-like receptor (TLR) 7, a key component of the innate immune response with downstream signaling effects involving the adaptive immune response. It is FDA-approved for the treatment superficial basal cell carcinomas, actinic keratoses, and genital warts. Finally, tape stripping is a validated procedure used to remove

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>